US Food and Drug Administration officials are thinking about ways to ensure the randomized, placebo-controlled Phase III clinical trials for coronavirus vaccine candidates can continue even after a product successfully completes the regulatory process.
Once the FDA approves or grants an emergency use authorization to make a vaccine available, trial enrollment may become much...